Concepts (296)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nicotine | 87 | 2020 | 157 | 21.540 |
Why?
|
| Smoking | 42 | 2019 | 427 | 10.630 |
Why?
|
| Smoking Cessation | 34 | 2019 | 118 | 10.210 |
Why?
|
| Tobacco Use Disorder | 39 | 2019 | 76 | 8.500 |
Why?
|
| Nicotinic Agonists | 25 | 2019 | 48 | 3.650 |
Why?
|
| Substance Withdrawal Syndrome | 15 | 2018 | 53 | 3.540 |
Why?
|
| Conditioning, Operant | 26 | 2017 | 96 | 3.370 |
Why?
|
| Tobacco | 7 | 2018 | 50 | 1.960 |
Why?
|
| Self Administration | 42 | 2020 | 296 | 1.840 |
Why?
|
| Double-Blind Method | 18 | 2019 | 503 | 1.800 |
Why?
|
| Male | 87 | 2020 | 17815 | 1.710 |
Why?
|
| Dose-Response Relationship, Drug | 35 | 2020 | 641 | 1.680 |
Why?
|
| Motivation | 11 | 2016 | 102 | 1.620 |
Why?
|
| Humans | 78 | 2019 | 29123 | 1.510 |
Why?
|
| Choice Behavior | 5 | 2016 | 83 | 1.500 |
Why?
|
| Rats | 42 | 2020 | 1604 | 1.470 |
Why?
|
| Adult | 41 | 2019 | 8426 | 1.450 |
Why?
|
| Rats, Sprague-Dawley | 36 | 2020 | 747 | 1.380 |
Why?
|
| Public Health | 5 | 2019 | 73 | 1.210 |
Why?
|
| Patient Compliance | 5 | 2018 | 208 | 1.200 |
Why?
|
| Alcohol Drinking | 4 | 2016 | 244 | 1.190 |
Why?
|
| Reward | 7 | 2015 | 63 | 1.160 |
Why?
|
| Young Adult | 17 | 2019 | 2402 | 1.150 |
Why?
|
| Female | 50 | 2020 | 18173 | 1.140 |
Why?
|
| Inhalation Exposure | 2 | 2016 | 6 | 1.100 |
Why?
|
| Animals | 52 | 2020 | 7299 | 1.090 |
Why?
|
| Cocaine | 6 | 2014 | 264 | 1.080 |
Why?
|
| Reinforcement Schedule | 14 | 2015 | 60 | 1.070 |
Why?
|
| Tobacco Industry | 3 | 2014 | 16 | 1.060 |
Why?
|
| Weight Gain | 4 | 2018 | 108 | 0.980 |
Why?
|
| Cues | 11 | 2014 | 67 | 0.980 |
Why?
|
| Government Regulation | 4 | 2016 | 35 | 0.950 |
Why?
|
| Middle Aged | 25 | 2019 | 10834 | 0.930 |
Why?
|
| Cotinine | 6 | 2017 | 45 | 0.920 |
Why?
|
| Health Policy | 4 | 2016 | 80 | 0.850 |
Why?
|
| Behavior, Animal | 10 | 2016 | 264 | 0.800 |
Why?
|
| Depression | 2 | 2016 | 382 | 0.720 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2019 | 464 | 0.700 |
Why?
|
| Discrimination Learning | 2 | 2016 | 20 | 0.700 |
Why?
|
| Commerce | 2 | 2016 | 37 | 0.690 |
Why?
|
| Adolescent | 14 | 2019 | 3255 | 0.690 |
Why?
|
| Monoamine Oxidase Inhibitors | 2 | 2016 | 3 | 0.680 |
Why?
|
| Alkaloids | 2 | 2016 | 9 | 0.680 |
Why?
|
| Behavior | 3 | 2015 | 29 | 0.660 |
Why?
|
| Photic Stimulation | 8 | 2012 | 155 | 0.640 |
Why?
|
| Product Labeling | 1 | 2017 | 12 | 0.620 |
Why?
|
| Risk-Taking | 1 | 2017 | 91 | 0.590 |
Why?
|
| Eating | 4 | 2018 | 73 | 0.590 |
Why?
|
| Cocaine-Related Disorders | 4 | 2009 | 106 | 0.590 |
Why?
|
| Benzazepines | 3 | 2014 | 22 | 0.590 |
Why?
|
| Models, Theoretical | 1 | 2018 | 126 | 0.580 |
Why?
|
| Tranylcypromine | 2 | 2016 | 2 | 0.580 |
Why?
|
| Harm Reduction | 1 | 2016 | 11 | 0.580 |
Why?
|
| Body Weight | 4 | 2018 | 290 | 0.570 |
Why?
|
| Sucrose | 3 | 2020 | 17 | 0.570 |
Why?
|
| Marijuana Smoking | 1 | 2016 | 37 | 0.560 |
Why?
|
| Disease Models, Animal | 9 | 2020 | 980 | 0.560 |
Why?
|
| Neostriatum | 1 | 2015 | 21 | 0.550 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2017 | 326 | 0.550 |
Why?
|
| Receptors, Nicotinic | 5 | 2007 | 60 | 0.540 |
Why?
|
| Acetaldehyde | 1 | 2015 | 4 | 0.540 |
Why?
|
| Quinoxalines | 2 | 2014 | 13 | 0.540 |
Why?
|
| Carbolines | 1 | 2015 | 9 | 0.540 |
Why?
|
| Heart Rate | 4 | 2012 | 315 | 0.520 |
Why?
|
| Biomedical Research | 1 | 2016 | 153 | 0.520 |
Why?
|
| United States | 11 | 2017 | 3632 | 0.500 |
Why?
|
| Conditioning, Classical | 1 | 2014 | 24 | 0.490 |
Why?
|
| Learning | 1 | 2015 | 76 | 0.490 |
Why?
|
| Task Performance and Analysis | 1 | 2014 | 51 | 0.490 |
Why?
|
| Methadone | 2 | 2005 | 12 | 0.490 |
Why?
|
| Token Economy | 1 | 2013 | 1 | 0.480 |
Why?
|
| Behavior, Addictive | 5 | 2018 | 29 | 0.480 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 4 | 2008 | 25 | 0.480 |
Why?
|
| Saccades | 1 | 2014 | 21 | 0.480 |
Why?
|
| Caudate Nucleus | 1 | 2013 | 23 | 0.470 |
Why?
|
| Self Efficacy | 3 | 2008 | 70 | 0.470 |
Why?
|
| Opioid-Related Disorders | 2 | 2005 | 50 | 0.460 |
Why?
|
| Animal Experimentation | 1 | 2012 | 6 | 0.440 |
Why?
|
| Health Behavior | 1 | 2014 | 214 | 0.440 |
Why?
|
| Blood Pressure | 4 | 2012 | 806 | 0.440 |
Why?
|
| Decision Making | 1 | 2014 | 180 | 0.420 |
Why?
|
| Analgesics, Opioid | 2 | 2005 | 239 | 0.390 |
Why?
|
| United States Food and Drug Administration | 3 | 2015 | 44 | 0.380 |
Why?
|
| Brain | 3 | 2014 | 930 | 0.370 |
Why?
|
| Analysis of Variance | 7 | 2017 | 454 | 0.370 |
Why?
|
| Aged | 8 | 2017 | 9492 | 0.350 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2016 | 1219 | 0.340 |
Why?
|
| Acetylcysteine | 2 | 2019 | 11 | 0.340 |
Why?
|
| Extinction, Psychological | 5 | 2009 | 19 | 0.330 |
Why?
|
| Phobic Disorders | 1 | 2008 | 8 | 0.320 |
Why?
|
| Nicotinic Antagonists | 6 | 2012 | 19 | 0.320 |
Why?
|
| Time Factors | 8 | 2016 | 2001 | 0.310 |
Why?
|
| Personal Satisfaction | 1 | 2007 | 25 | 0.300 |
Why?
|
| Creatinine | 2 | 2018 | 174 | 0.290 |
Why?
|
| Association Learning | 8 | 2016 | 16 | 0.290 |
Why?
|
| Schizophrenia | 2 | 2020 | 38 | 0.290 |
Why?
|
| Substance-Related Disorders | 2 | 2006 | 113 | 0.280 |
Why?
|
| Ganglionic Stimulants | 4 | 2016 | 7 | 0.270 |
Why?
|
| Comorbidity | 4 | 2015 | 540 | 0.270 |
Why?
|
| Central Nervous System Stimulants | 1 | 2006 | 74 | 0.260 |
Why?
|
| Mecamylamine | 6 | 2012 | 13 | 0.260 |
Why?
|
| Carbon Monoxide | 2 | 2018 | 6 | 0.260 |
Why?
|
| Substance Abuse, Intravenous | 2 | 2009 | 27 | 0.250 |
Why?
|
| Oxygen | 2 | 2016 | 139 | 0.240 |
Why?
|
| Infusions, Intravenous | 7 | 2016 | 85 | 0.240 |
Why?
|
| Neural Pathways | 2 | 2016 | 97 | 0.240 |
Why?
|
| Linear Models | 2 | 2015 | 426 | 0.240 |
Why?
|
| Prefrontal Cortex | 2 | 2014 | 69 | 0.230 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2016 | 242 | 0.230 |
Why?
|
| Prevalence | 4 | 2016 | 898 | 0.230 |
Why?
|
| Affect | 3 | 2009 | 63 | 0.230 |
Why?
|
| Dinoprost | 2 | 2019 | 10 | 0.220 |
Why?
|
| Heroin | 1 | 2002 | 14 | 0.210 |
Why?
|
| Random Allocation | 2 | 2013 | 213 | 0.210 |
Why?
|
| Pyridines | 3 | 2016 | 78 | 0.200 |
Why?
|
| Food | 3 | 2016 | 41 | 0.200 |
Why?
|
| Adolescent Behavior | 2 | 2016 | 57 | 0.200 |
Why?
|
| Dopamine Uptake Inhibitors | 3 | 2009 | 120 | 0.200 |
Why?
|
| Estrus | 1 | 2000 | 5 | 0.190 |
Why?
|
| Oxidative Stress | 2 | 2019 | 223 | 0.190 |
Why?
|
| Methylazoxymethanol Acetate | 1 | 2020 | 1 | 0.190 |
Why?
|
| Saliva | 2 | 2017 | 36 | 0.180 |
Why?
|
| Causality | 3 | 2008 | 37 | 0.180 |
Why?
|
| Dinoprostone | 1 | 2019 | 37 | 0.180 |
Why?
|
| Eicosanoids | 1 | 2019 | 7 | 0.180 |
Why?
|
| Hazardous Substances | 1 | 2019 | 1 | 0.170 |
Why?
|
| Marketing | 1 | 2019 | 24 | 0.170 |
Why?
|
| Bupropion | 2 | 2009 | 5 | 0.170 |
Why?
|
| Obesity | 2 | 2017 | 1063 | 0.170 |
Why?
|
| Phenanthrenes | 1 | 2018 | 3 | 0.170 |
Why?
|
| Inflammation | 2 | 2019 | 507 | 0.170 |
Why?
|
| Recurrence | 3 | 2015 | 235 | 0.170 |
Why?
|
| Breath Tests | 1 | 2018 | 17 | 0.170 |
Why?
|
| Public Policy | 1 | 2018 | 34 | 0.170 |
Why?
|
| Smoke | 1 | 2018 | 12 | 0.170 |
Why?
|
| Individuality | 2 | 2015 | 5 | 0.170 |
Why?
|
| Area Under Curve | 1 | 2018 | 85 | 0.160 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2016 | 92 | 0.160 |
Why?
|
| C-Reactive Protein | 1 | 2019 | 232 | 0.160 |
Why?
|
| Immune System | 1 | 1998 | 8 | 0.160 |
Why?
|
| Feeding Behavior | 3 | 2018 | 159 | 0.160 |
Why?
|
| Immunity | 1 | 1998 | 19 | 0.160 |
Why?
|
| Drug Administration Schedule | 4 | 2007 | 246 | 0.150 |
Why?
|
| Terminology as Topic | 1 | 2017 | 62 | 0.150 |
Why?
|
| Glucuronosyltransferase | 1 | 2017 | 5 | 0.150 |
Why?
|
| Lipid Metabolism | 1 | 2018 | 100 | 0.150 |
Why?
|
| Patient Dropouts | 1 | 2017 | 24 | 0.150 |
Why?
|
| Psychopharmacology | 1 | 2016 | 2 | 0.150 |
Why?
|
| New Zealand | 1 | 2016 | 8 | 0.150 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2016 | 1 | 0.150 |
Why?
|
| History, 21st Century | 1 | 2016 | 48 | 0.150 |
Why?
|
| History, 20th Century | 1 | 2016 | 68 | 0.140 |
Why?
|
| World Health Organization | 1 | 2016 | 15 | 0.140 |
Why?
|
| Lithium Chloride | 1 | 2016 | 2 | 0.140 |
Why?
|
| Anabasine | 1 | 2016 | 1 | 0.140 |
Why?
|
| Severity of Illness Index | 3 | 2008 | 863 | 0.140 |
Why?
|
| Rest | 1 | 2016 | 49 | 0.140 |
Why?
|
| Tars | 1 | 2015 | 2 | 0.140 |
Why?
|
| Age Factors | 1 | 2019 | 1108 | 0.140 |
Why?
|
| Tobacco Use Cessation | 1 | 2015 | 13 | 0.140 |
Why?
|
| Research Design | 1 | 2017 | 286 | 0.130 |
Why?
|
| Brain Mapping | 1 | 2016 | 182 | 0.130 |
Why?
|
| Cross-Sectional Studies | 3 | 2008 | 1362 | 0.130 |
Why?
|
| Impulsive Behavior | 2 | 2012 | 7 | 0.130 |
Why?
|
| Genetic Variation | 2 | 2017 | 251 | 0.130 |
Why?
|
| Injections, Subcutaneous | 2 | 2012 | 33 | 0.120 |
Why?
|
| Parietal Lobe | 1 | 2014 | 16 | 0.120 |
Why?
|
| Gyrus Cinguli | 1 | 2014 | 22 | 0.120 |
Why?
|
| Frontal Lobe | 1 | 2014 | 45 | 0.120 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 2109 | 0.120 |
Why?
|
| Statistics as Topic | 1 | 2013 | 106 | 0.120 |
Why?
|
| Mental Disorders | 1 | 2014 | 103 | 0.120 |
Why?
|
| Health Promotion | 1 | 2015 | 220 | 0.110 |
Why?
|
| Rodentia | 1 | 2012 | 10 | 0.110 |
Why?
|
| Demography | 1 | 2012 | 104 | 0.110 |
Why?
|
| Social Environment | 3 | 2009 | 75 | 0.110 |
Why?
|
| Alcoholism | 2 | 2010 | 95 | 0.110 |
Why?
|
| Risk Factors | 3 | 2008 | 3537 | 0.100 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2012 | 80 | 0.100 |
Why?
|
| Pilot Projects | 1 | 2012 | 469 | 0.100 |
Why?
|
| Students | 3 | 2008 | 168 | 0.100 |
Why?
|
| Regression Analysis | 2 | 2008 | 274 | 0.100 |
Why?
|
| Attitude | 1 | 2009 | 37 | 0.090 |
Why?
|
| Age of Onset | 1 | 2009 | 95 | 0.090 |
Why?
|
| Administration, Cutaneous | 1 | 2009 | 107 | 0.080 |
Why?
|
| Child | 3 | 2010 | 2219 | 0.080 |
Why?
|
| Naltrexone | 1 | 2008 | 38 | 0.080 |
Why?
|
| Injections, Intravenous | 2 | 2006 | 73 | 0.080 |
Why?
|
| Narcotic Antagonists | 1 | 2008 | 50 | 0.080 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2007 | 26 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2015 | 1306 | 0.080 |
Why?
|
| Mental Health | 1 | 2008 | 104 | 0.070 |
Why?
|
| Ethnic Groups | 1 | 2009 | 440 | 0.070 |
Why?
|
| Probability | 1 | 2007 | 150 | 0.070 |
Why?
|
| Behavioral Research | 1 | 2006 | 4 | 0.070 |
Why?
|
| Acetylcholine | 1 | 2006 | 47 | 0.070 |
Why?
|
| Health Surveys | 1 | 2007 | 191 | 0.070 |
Why?
|
| Guidelines as Topic | 1 | 2006 | 45 | 0.070 |
Why?
|
| Phenotype | 3 | 2017 | 629 | 0.070 |
Why?
|
| Sleep | 1 | 2007 | 87 | 0.070 |
Why?
|
| Risk | 1 | 2007 | 289 | 0.070 |
Why?
|
| Cross-Over Studies | 2 | 2003 | 94 | 0.070 |
Why?
|
| Heroin Dependence | 1 | 2005 | 4 | 0.070 |
Why?
|
| Models, Animal | 2 | 2016 | 160 | 0.070 |
Why?
|
| Aging | 1 | 2012 | 881 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 493 | 0.070 |
Why?
|
| Protein Binding | 1 | 2004 | 199 | 0.060 |
Why?
|
| Sex Characteristics | 2 | 2005 | 167 | 0.060 |
Why?
|
| Arousal | 1 | 2003 | 19 | 0.060 |
Why?
|
| Lighting | 1 | 2002 | 3 | 0.060 |
Why?
|
| Receptors, Dopamine D1 | 1 | 2001 | 19 | 0.050 |
Why?
|
| Dopamine Antagonists | 1 | 2001 | 23 | 0.050 |
Why?
|
| Corticosterone | 1 | 2000 | 9 | 0.050 |
Why?
|
| Radioimmunoassay | 1 | 2000 | 21 | 0.050 |
Why?
|
| Epinephrine | 1 | 2000 | 41 | 0.050 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2020 | 12 | 0.050 |
Why?
|
| Norepinephrine | 1 | 2000 | 73 | 0.050 |
Why?
|
| Hospitalization | 1 | 2003 | 417 | 0.050 |
Why?
|
| Animals, Newborn | 1 | 2020 | 111 | 0.040 |
Why?
|
| Erythrocyte Indices | 1 | 2019 | 3 | 0.040 |
Why?
|
| Erythrocyte Count | 1 | 2019 | 6 | 0.040 |
Why?
|
| Platelet Count | 1 | 2019 | 21 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2019 | 55 | 0.040 |
Why?
|
| F2-Isoprostanes | 1 | 2019 | 20 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2019 | 68 | 0.040 |
Why?
|
| Acrolein | 1 | 2019 | 1 | 0.040 |
Why?
|
| Acrylonitrile | 1 | 2019 | 1 | 0.040 |
Why?
|
| Toxicology | 1 | 2019 | 6 | 0.040 |
Why?
|
| Metabolome | 1 | 2019 | 31 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2000 | 364 | 0.040 |
Why?
|
| Calorimetry | 1 | 2018 | 3 | 0.040 |
Why?
|
| Injections, Intraperitoneal | 2 | 2007 | 41 | 0.040 |
Why?
|
| Glucuronides | 1 | 2017 | 2 | 0.040 |
Why?
|
| Philadelphia | 1 | 2017 | 5 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2017 | 56 | 0.040 |
Why?
|
| Urinalysis | 1 | 2016 | 19 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1998 | 148 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 721 | 0.040 |
Why?
|
| Universities | 2 | 2008 | 142 | 0.040 |
Why?
|
| Dietary Fats | 1 | 2017 | 108 | 0.040 |
Why?
|
| Monoamine Oxidase | 1 | 2016 | 5 | 0.040 |
Why?
|
| Infusions, Parenteral | 1 | 2016 | 64 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2016 | 53 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2016 | 93 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2016 | 57 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2019 | 865 | 0.030 |
Why?
|
| Corpus Striatum | 1 | 2016 | 60 | 0.030 |
Why?
|
| Visual Perception | 2 | 2007 | 112 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2008 | 726 | 0.030 |
Why?
|
| Genotype | 1 | 2017 | 735 | 0.030 |
Why?
|
| Dangerous Behavior | 1 | 2014 | 3 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2017 | 1131 | 0.030 |
Why?
|
| Research | 1 | 2012 | 72 | 0.030 |
Why?
|
| Basal Ganglia | 1 | 2012 | 15 | 0.030 |
Why?
|
| Continental Population Groups | 1 | 2012 | 221 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2012 | 196 | 0.020 |
Why?
|
| Prazosin | 1 | 2009 | 9 | 0.020 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2009 | 27 | 0.020 |
Why?
|
| Skin Temperature | 1 | 2009 | 15 | 0.020 |
Why?
|
| African Americans | 1 | 2017 | 1373 | 0.020 |
Why?
|
| Exploratory Behavior | 1 | 2009 | 30 | 0.020 |
Why?
|
| Safety | 1 | 2009 | 72 | 0.020 |
Why?
|
| Personal Autonomy | 1 | 2008 | 9 | 0.020 |
Why?
|
| Filtration | 1 | 2008 | 2 | 0.020 |
Why?
|
| Social Perception | 1 | 2008 | 21 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 727 | 0.020 |
Why?
|
| Water | 1 | 2008 | 50 | 0.020 |
Why?
|
| Administration, Inhalation | 1 | 2008 | 92 | 0.020 |
Why?
|
| Reference Values | 1 | 2008 | 224 | 0.020 |
Why?
|
| Psychometrics | 1 | 2008 | 129 | 0.020 |
Why?
|
| Thiazoles | 1 | 2007 | 32 | 0.020 |
Why?
|
| Patient Selection | 1 | 2009 | 257 | 0.020 |
Why?
|
| Dihydro-beta-Erythroidine | 1 | 2007 | 1 | 0.020 |
Why?
|
| Aconitine | 1 | 2007 | 5 | 0.020 |
Why?
|
| Infusion Pumps | 1 | 2007 | 5 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2008 | 163 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2014 | 3101 | 0.020 |
Why?
|
| Brain Chemistry | 1 | 2006 | 30 | 0.020 |
Why?
|
| Species Specificity | 1 | 2006 | 84 | 0.020 |
Why?
|
| Child of Impaired Parents | 1 | 2006 | 3 | 0.020 |
Why?
|
| Fathers | 1 | 2006 | 11 | 0.020 |
Why?
|
| Marijuana Abuse | 1 | 2006 | 18 | 0.020 |
Why?
|
| Remission Induction | 1 | 2006 | 78 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2006 | 379 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2005 | 97 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2009 | 568 | 0.020 |
Why?
|
| Models, Biological | 1 | 2006 | 373 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 787 | 0.020 |
Why?
|
| Sex Factors | 1 | 2006 | 631 | 0.020 |
Why?
|
| Disease Progression | 1 | 2006 | 572 | 0.010 |
Why?
|
| Environment, Controlled | 1 | 2002 | 3 | 0.010 |
Why?
|
| Environment | 1 | 2002 | 51 | 0.010 |
Why?
|
| Receptors, Dopamine D5 | 1 | 2001 | 2 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2001 | 148 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 2000 | 36 | 0.010 |
Why?
|
| Mice | 1 | 1998 | 2370 | 0.010 |
Why?
|